Clincosm LogoSign in Get a demo

gastroesophageal junction adenocarcinoma

Showing NaN - NaN of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, Beijing, China
  • +10 more
Nov 23, 2023

Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Serplulimab)

Recruiting
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, China
    Peking Union Medical College Hospital
Jun 15, 2023

Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)

Active, not recruiting
  • Stomach Neoplasms
  • +2 more
  • Beijing, China
  • +10 more
Dec 21, 2022

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (CS1001 mAb, CS1001 , Oxaliplatin)

Active, not recruiting
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • CS1001 monoclonal antibody
  • +3 more
  • Beijing, China
    Beijing Cancer Hospital
Sep 27, 2022

Gastric Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Pembrolizumab, Paclitaxel)

Terminated
  • Gastric Neoplasms
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, Beijing, China
  • +35 more
Apr 1, 2022

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Trastuzumab, Capecitabine)

Recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, China
  • +9 more
Mar 11, 2022

Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (CT041 autologous CAR T-cell

Recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • CT041 autologous CAR T-cell injection
  • Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
  • Hefei, Anhui, China
  • +9 more
Feb 13, 2022

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Raltitrexed, Paclitaxel)

Completed
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Beijing, China
    Chinese Academy of Medical Sciences
Jan 29, 2021

Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (AK104, Oxaliplatin,

Unknown status
  • Gastric Adenocarcinoma
  • +2 more
  • AK104
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Feb 22, 2019